Specialty Pharmaceutical Hub Services Providers 2019 Report
Walmart and Home Depot, two of the top 10 U.S. employers, are using copay accumulator programs
CVS Health’s Dilemma with Omnicare Continues. CVS Health is targeting upward of $150 million in “cost takeout opportunities.”
Specialty Pharmacy Market Overview – Market Shakeout Continuing into 2018 As the specialty drug spend grows, specialty pharmacies are playing an increasingly larger role in access and delivery of medications and services. The specialty pharmacy market, while dominated by a few large companies, has an increasing number of participants. AMI’s annual report, Specialty Pharmacy Market […]
Metro Areas Where Employers Influence Cancer Coverage Costs. Employers currently represent approximately 60% of the commercial insurance market dollars. The Employer commercial insurance market consists of more than 95,000 companies with self-insured plans, eighty percent of whom have less than 2,000 employees. Entering 2017, these employers face double-digit increases in the cost of prescription drugs […]
Amber Specialty Pharmacy leads patient satisfaction. Amber Pharmacy, a wholly owned subsidiary of Hy-Vee, is the No. 1 ranked specialty pharmacy in the U.S. for patient satisfaction with pharmacy employees, according to a recent Zitter Health Insights survey. The survey assessed numerous aspects of patient satisfaction and garnered responses from more than 3,000 patients across 38 […]
Limited Distribution Networks growth continues as Specialty Pharmacies compete to be chosen to distribute specialty pharmaceuticals. AMI’s report, Distribution Decision-Making for Specialty Drugs, found that Pharmaceutical manufacturers typically develop a product-specific distribution strategy dependent on company-specific criteria when bringing a new specialty drug to the market. Pharmaceutical manufacturers consider approximately 100-150 different specialty pharmacies (SPs) […]
Future of Specialty Pharmacy – Recent events involving Valeant and Philidor have caused an uproar in the marketplace along with the Turing Pharmaceutical (and generics) mess around pricing. Now the NY Times casts the light on Horizon and Linden illustrating the bad without much good around stakeholder relationships that pharma firms have utilized. Due to the evolution […]